GlassScriptPhysician profile
Danielle Dutcher Murphy
NPI 1104221969
$2,756.61
in general payments reported to CMS, 2019-2025
23 companies · $693 in 2025
The $693 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $327 · 2023: $381 · 2024: $640 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $440.58 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Pfizer INC. | $365.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $343.32 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.65 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $201.06 | 2024-2025 | Wegovy, Ozempic |
| Amgen INC. | $154.62 | 2022-2023 | Repatha |
| Corcept Therapeutics | $143.16 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $109.04 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $103.35 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $100.79 | 2022-2024 | Camzyos |
| Impulse Dynamics (USA) INC. | $87.46 | 2023 | Optimizer |
| Boston Scientific Corporation | $77.70 | 2024 | Watchman Flx, Bodyguardian |
| Kiniksa Pharmaceuticals, LTD. | $69.41 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.99 | 2022-2024 | Jardiance |
| Amarin Pharma, INC. | $58.74 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $33.55 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $32.05 | 2022 | |
| Soleno Therapeutics, INC. | $29.92 | 2025 | Vykat Xr |
| Actelion Pharmaceuticals US, INC. | $27.60 | 2024 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $25.14 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $20.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.47 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.